Intracellular Ganciclovir Triphosphate Concentrations in Children With Congenital Cytomegalovirus Infection
The Journal of Infectious Diseases · 2025
DOI: 10.1093/infdis/jiaf633 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Infectious Diseases, 2025. Verfasst von Brent Lindquist-Kleissler und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Human Toxicology, Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Ganciclovir, Antiviral Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH/NIDCD.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background
Congenital cytomegalovirus (cCMV) infection is the most common cause of nonhereditary pediatric sensorineural hearing loss (SNHL). Importantly, cCMV is treatable, with the primary option being ganciclovir (GCV) or its orally bioavailable pro-drug valganciclovir (VGCV). A challenge for treating cCMV is the elevated risk for neutropenia associated with standard dosing. Optimizing and individualizing (V)GCV dosing could ameliorate the risk of neutropenia and improve efficacy but requires an understanding of the complex intracellular phosphorylation processes that govern the formation of the active GCV-triphosphate (GCV-TP) moiety. This study utilizes dried blood spot (DBS) samples from infants with cCMV to quantify GCV-TP and explore the kinetics of GCV-TP in this matrix.
Methods
DBS samples were collected from infants with cCMV infection receiving 16 mg/kg VGCV twice daily as part of either a randomized, placebo-controlled clinical trial (ValEAR) or an open-label PK study. GCV-TP concentrations in DBS were determined using LC-MS/MS.
Results
Data indicate that GCV-TP is long-lived in DBS, with a half-life approximating 21 days. This leads to extensive GCV-TP accumulation in this matrix (primarily consisting of erythrocytes), with an expected approximately 62-fold difference in first-dose and steady-state concentrations. Simulated data highlight the potential for DBS GCV-TP to be used as an objective adherence marker.
Conclusions
These findings underscore the need to define the kinetics of GCV-TP in cell matrices relevant to its activity to determine appropriate VGCV dosing strategies in this population and establish safe and define effective therapeutic concentration targets.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Human Toxicology, Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah, USA.
- Department of Otolaryngology-Head and Neck Surgery, University of Utah, Salt Lake City, Utah, USA.
- Department of Pediatrics, University of Utah, Salt Lake City, Utah, USA.
ORCID-Profile: Brent Lindquist-Kleissler, Peter Kfoury, Keith T Kuo, Albert H Park, Joseph E Rower
Förderung
- NIH/NIDCD
Zitieren
APA
Lindquist-Kleissler, B., Kfoury, P., Kuo, K. T., Elwood, C., Wilkes, A., Park, A. H., & Rower, J. E. (2025). Intracellular Ganciclovir Triphosphate Concentrations in Children With Congenital Cytomegalovirus Infection. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf633
Vancouver
Lindquist-Kleissler B, Kfoury P, Kuo KT, Elwood C, Wilkes A, Park AH, et al. Intracellular Ganciclovir Triphosphate Concentrations in Children With Congenital Cytomegalovirus Infection. The Journal of Infectious Diseases. 2025. doi:10.1093/infdis/jiaf633
BibTeX
@article{LindquistKleissler2025,
author = {Lindquist-Kleissler, Brent and Kfoury, Peter and Kuo, Keith T and Elwood, Cameron and Wilkes, Ashlea and Park, Albert H and Rower, Joseph E},
title = {Intracellular Ganciclovir Triphosphate Concentrations in Children With Congenital Cytomegalovirus Infection},
journal = {The Journal of Infectious Diseases},
year = {2025},
doi = {10.1093/infdis/jiaf633}
}
EUVIMED